About City of Hope

City of Hope is an independent biomedical research and treatment organization for cancer, diabetes and other life-threatening diseases.

Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution.  AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.

A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.

City of Hope’s commitment to Diversity, Equity and Inclusion

We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities.  Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding.  We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.

Position Summary

Dr. David Chen’s research group at the Beckman Research Institute of City of Hope is looking for a talented Postdoctoral Fellow. Dr. Chen is the Director of Division of Epigenetics and Transcriptional Engineering at City of Hope. His lab focuses on epigenetic mechanisms, drug resistance, and therapeutic target discovery in cancers using high throughput genetic screens. This laboratory is skilled in high-throughput CRISPR genetic screens for de novo therapeutic target discovery. They also utilize next-generation sequencing (NGS) for epigenomic and transcriptomic analyses (ChIPseq, ATACseq, RNAseq, etc.), and the patient-derived xenograft (PDX) models for in vivo therapeutic efficacy assessments. In addition, Dr. Chen’s laboratory is involved in cutting-edge technology development including high-density CRISPR protein scan, precision epigenome editing, and single-cell CRISPR/RNA-seq. The lab is well funded by the NIH (R37 MERIT, R01s, U54) and foundation (ASH, LLS, ALSF, COSF, SU2C-CRUK) awards.

Basic education, experience and skills required for consideration:

• A Ph.D. degree in life or biomedical sciences, or a related discipline (cancer biology, structural biology, computational biology, bioinformatics) is required.
• Good oral and written communication skills in English.

Preferred education, experience and skills required for consideration:

• Experience in cell biology, molecular cloning, or animal model studies (highly preferred).
• Experience in transcriptomic, proteomic, epigenetic, molecular dynamic, or protein structural data analysis (highly preferred).
• Experience in protein purification, compound screen, protein/protein or protein/compound interaction (highly preferred).
• Experience in R, Python, Perl, UNIX/LINUX, etc. (highly preferred).

Additional Information:

• As a condition of employment, City of Hope requires staff to comply with all state and federal vaccination mandates.  
• For more information on Dr. David Chen’s research, please visit here.

City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer.  All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.

#PD